A discrete choice experiment was conducted among general practitioners, cardiologists, neurologists and ophthalmologists in Germany to examine physicians’ preferences regarding adherence-promoting programs (APPs). The design considered five attributes with two or three attribute levels each: validation status of the APP; possibility for physicians to receive a certificate; type of intervention; time commitment per patient and quarter of the year to carry out the APP; reimbursement for APP participation, per included patient and quarter of the year.

The patient’s perspective is becoming increasingly important in clinical and policy decisions. This study examined atrial fibrillation (AF) patient preferences for different characteristics of nonvitamin K antagonist oral anticoagulants (NOACs).

As there is a general lack of data around T2DM patients newly initiating an insulin therapy, it was the main objective of this study to collect these data. The main strength of this analysis is the use of a large claims dataset unaffected by any selection bias and an additional collection of MCR data for reasons of a validity check of claims data analysis results, as the claims data specifically addressed two German states.

The aim of this investigation was to develop and validate a respective questionnaire (Adherence Barriers Questionnaire for HIV: ABQ-HIV), based on an earlier version of the ABQ.

The study showed that the ABQ-HIV is a practical, reliable, and valid instrument for identifying patient-specific barriers to

adherence in the HIV treatment that is also useful in identifying HIV patient subgroups.

This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.

Real-world evidence (RWE) can inform patient management decisions, but RWE studies are associated with limitations. Linkage of different RWE data types could address such limitations by enriching data and improving scientific quality. Using the example of chronic obstructive pulmonary disease (COPD) in Germany, this study assessed the value of data linkage between primary and secondary data sources for RWE.

The aim of this study was to assess patients’ views and xpectations with regard to neovascular age-related macular degeneration (nAMD) and intravitreal anti-VEGF therapy (IVT).

This multicenter, non-interventional, prospective cohort study showed that only a minority of patients are aware of the chronic nature of nAMD. To motivate patients to accept a life-long IVT treatment, physicians and caregivers must know that there exist different patient types with significant differences in communication needs.

Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients’ preferences regarding the type of medication, particularly given the established relationship between preferences towards treatment, associated burden of therapy, and treatment adherence. This review aimed to systematically analyze the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment.

We used two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012) to assess the level of persistence and adherence to therapy with glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes mellitus (T2DM) patients in the United Kingdom (UK) and Germany, also by comparing once- (OD) with twice-a-day (BID) therapy.

Medication non-adherence is a major challenge in the real-life treatment of chronically ill patients. To meet this challenge, adherence interventions with a tailored approach towards patient-specific adherence barriers identified with a reliable and practicable questionnaire are needed. This investigation aimed to develop and validate such a questionnaire, the “Adherence Barriers Questionnaire (ABQ)”.

According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens are unknown. We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis and (2) whether specific independent factors explain NA.